Industry

Johnson & Johnson Marks 10 Million Implants for Tecnis Eyhance IOL

Eyewire+3h ago2 min read

Johnson & Johnson announced that its Tecnis Eyhance IOL, which the company describes as the first enhanced monofocal IOL, has been implanted in more than 10 million eyes worldwide. “Reaching over 10 million implants is not just a volume milestone—it is validation that Tecnis Eyhance IOL delivers consistent, real-world outcomes at scale,” said Paul Lisenby, Global Head of R&D, Vision at Johnson & Johnson. “That level of adoption reflects years of clinical evidence, surgeon trust, and performance under everyday visual conditions.” Since its global debut in 2019, Tecnis Eyhance IOL is designed to slightly extend depth of focus while maintaining high-quality distance vision and contrast sensitivity under a range of lighting conditions. Built on the long-standing Tecnis platform—used in ophthalmology for more than 25 years—the Eyhance lens is designed to incorporates a continuous power profile to enhance intermediate vision while preserving distance clarity. Clinical studies supporting the lens include: More than 26 studies demonstrating excellent contrast sensitivity, including performance in low-light conditions Over 48 studies highlighting improved intermediate vision outcomes More than 20 studies reporting low incidence of visual disturbances such as halos, glare, and starbursts Tecnis Eyhance IOL is part of Johnson & Johnson’s broader Tecnis portfolio, which combines advanced optical design with proprietary materials. The lineup also includes newer offerings such as the Tecnis PureSee IOL, a purely refractive extended depth of focus (EDOF) lens, and the Tecnis Odyssey IOL, designed to deliver a full visual range. Johnson & Johnson is presenting new clinical data on both Tecnis PureSee and Tecnis Odyssey IOLs at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) 2026 meeting.

Read full article on Eyewire+

AI Summary

Quick Take

Johnson & Johnson’s Tecnis Eyhance IOL has surpassed 10 million implants globally since its 2019 debut, solidifying its position as a leading "enhanced monofocal" option. The lens utilizes a continuous power profile to improve intermediate vision without sacrificing the distance clarity or contrast sensitivity typical of standard monofocal lenses.

Why It Matters

The "enhanced monofocal" category has fundamentally changed the conversation around cataract surgery by offering patients functional intermediate vision—useful for computer work and dashboards—without the dysphotopsias often associated with traditional multifocal or EDOF lenses. Reaching 10 million implants suggests that surgeons have largely embraced this as a "standard-plus" option for patients who are risk-averse regarding glare and halos but desire more than just distance correction. It validates the shift in the industry toward refractive outcomes even in standard cataract procedures.

Key Details

The Tecnis Eyhance is built on the established Tecnis platform, which has been utilized in ophthalmology for over 25 years.
The lens features a continuous power profile designed to slightly extend the depth of focus for tasks like using a tablet or driving.
Clinical backing includes over 48 studies specifically highlighting improved intermediate vision outcomes compared to standard monofocals.
More than 20 studies confirm a low incidence of visual disturbances, such as halos, glare, and starbursts, comparable to traditional monofocal lenses.
The milestone reflects adoption across a broad range of lighting conditions, with 26 studies demonstrating maintained contrast sensitivity in low light.

Practice Implications

Clinicians can confidently position the Eyhance as a reliable upgrade for patients who prioritize distance clarity but would benefit from improved intermediate range for daily activities. Because it maintains a low side-effect profile similar to standard monofocals, it is a suitable consideration for patients who may not be ideal candidates for more aggressive EDOF or multifocal designs.

Who's Affected

OphthalmologistsCataract SurgeonsOptometristsPractice Owners

What's Next

Johnson & Johnson plans to present new clinical data on its newer portfolio additions, the Tecnis PureSee (a refractive EDOF) and Tecnis Odyssey (full visual range), at the ASCRS 2026 meeting. This indicates a continued push to refine the balance between range of vision and image quality.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.